Division of Genomics Research, Life Science Research Center, Gifu University, Gifu, Japan.
Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
J Hum Genet. 2019 Feb;64(2):145-152. doi: 10.1038/s10038-018-0512-1. Epub 2018 Sep 20.
The concept of peroxisomal diseases is expanding because of improvements in diagnostic technology based on advanced biochemical analysis and development of next-generation sequencing. For quicker and more accurate diagnosis of as many patients as possible, we developed a new diagnostic system combining the conventional diagnostic system and comprehensive mutational analysis by whole-exome sequencing in Japan. Adrenoleukodystrophy (ALD) is the most common peroxisomal disease. In the cerebral type of ALD, hematopoietic stem cell transplantation is the only treatment in the early stage, and thus prompt diagnosis will improve the prognosis of affected patients. Furthermore, it is also important to identify pre-symptomatic patients by family analysis of probands by providing appropriate disease information and genetic counseling, which will also lead to early intervention. Here, we summarize current information related to peroxisomal diseases and ALD and introduce our efficient diagnostic system for use in Japan, which resulted in the diagnosis of 73 Japanese patients with peroxisome biogenesis disorders, 16 with impaired β-oxidation of fatty acids, three with impaired etherphospholipid biosynthesis, and 191 Japanese families with ALD so far.
由于基于先进生化分析的诊断技术的改进和下一代测序的发展,过氧化物酶体疾病的概念正在不断扩大。为了尽可能快速和准确地诊断更多患者,我们在日本开发了一种新的诊断系统,将传统诊断系统与全外显子组测序的全面突变分析相结合。肾上腺脑白质营养不良(ALD)是最常见的过氧化物酶体疾病。在脑型 ALD 中,造血干细胞移植是早期唯一的治疗方法,因此及时诊断将改善患者的预后。此外,通过对先证者的家族进行分析,为其提供适当的疾病信息和遗传咨询,以识别出无症状前患者也很重要,这也将导致早期干预。在这里,我们总结了与过氧化物酶体疾病和 ALD 相关的最新信息,并介绍了我们在日本使用的高效诊断系统,该系统已诊断出 73 例日本过氧化物酶体生物发生障碍患者、16 例脂肪酸β氧化障碍患者、3 例醚磷脂生物合成障碍患者和 191 个日本 ALD 家系。